ACM
VRTX icon

Advisors Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisors Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$625K Buy
1,258
+120
+11% +$53.2K 0.01% 406
2026
Q1 		$509K Sell
1,138
-514
-31% -$240K 0.01% 388
2025
Q4 		$749K Buy
1,652
+100
+6% +$43.1K 0.01% 344
2025
Q3 		$608K Buy
1,552
+226
+17% +$94.5K 0.01% 360
2025
Q2 		$590K Buy
1,326
+55
+4% +$25.3K 0.01% 345
2025
Q1 		$616K Sell
1,271
-12,975
-91% -$6.05M 0.01% 335
2024
Q4 		$5.74M Sell
14,246
-295
-2% -$137K 0.09% 182
2024
Q3 		$6.76M Buy
14,541
+860
+6% +$413K 0.11% 167
2024
Q2 		$6.41M Sell
13,681
-45
-0.3% -$19.5K 0.11% 169
2024
Q1 		$5.74M Sell
13,726
-2,329
-15% -$985K 0.11% 173
2023
Q4 		$6.53M Buy
16,055
+2,754
+21% +$1.02M 0.13% 153
2023
Q3 		$4.63M Buy
+13,301
New +$4.65M 0.12% 162

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Advisors Capital Management's VRTX Position: Q2 2026 in Review

Advisors Capital Management increased its Vertex Pharmaceuticals (VRTX) stake by 11% in Q2 2026, buying an estimated $53.2K and bringing the position to 1,258 shares worth $625K. The position accounts for 0.01% of the portfolio, ranked #406.

Advisors Capital Management first reported a position in VRTX in Q3 2023 and has held it in 12 quarters since. The position peaked at $6.76M in Q3 2024. 1,762 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Advisors Capital Management held 1,258 shares of Vertex Pharmaceuticals worth $625K as of Q2 2026.
  • Advisors Capital Management bought 120 Vertex Pharmaceuticals shares in Q2 2026, an estimated $53.2K.
  • Vertex Pharmaceuticals made up 0.01% of Advisors Capital Management's portfolio in Q2 2026, its #406 holding.
  • Advisors Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2023 and has held it in 12 quarters since.
  • Advisors Capital Management's Vertex Pharmaceuticals position peaked at $6.76M in Q3 2024.
  • 1,762 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Advisors Capital Management's 13F filing for Q2 2026, filed 11 Aug 2026.